Case Comprehensive Cancer Center

Quick facts

Phase 3 pipeline

• Methotrexate (low dose) · Oncology; Immunology
  Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, blocking DNA synthesis and cell division in rapidly proliferating cells.
• O6-benzylguanine · Oncology
  O6-benzylguanine is an alkyltransferase inhibitor that depletes the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), sensitizing cancer cells to alkylating chemotherapy agents.
• recombinant interferon alfa-2b · Oncology
  Recombinant interferon alfa-2b works by stimulating the body's immune system to fight viral infections and cancer.
• tamsulosin and/or dutasteride · Urology
  Tamsulosin and dutasteride are alpha-1 adrenergic receptor antagonists and 5-alpha-reductase inhibitors, respectively, used to treat benign prostatic hyperplasia (BPH) symptoms and reduce the risk of acute urinary retention and BPH-related surgery.

Phase 1 pipeline

• Pembrolizumab at 35 days post

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Case Comprehensive Cancer Center portfolio CI brief
• Case Comprehensive Cancer Center pipeline updates RSS